Innovation Pharmaceuticals

Innovation Pharmaceuticals is a publicly traded, clinical-stage biopharmaceutical company focused on developing Brilacidin, a first-in-class defensin-mimetic with a unique multi-mechanistic profile. The company has achieved key milestones, including Fast Track designations from the FDA for COVID-19 and Oral Mucositis, a completed End-of-Phase 2 meeting for Oral Mucositis, and a licensing agreement with Alfasigma for Inflammatory Bowel Disease. Its strategy centers on advancing Brilacidin through clinical development for high-value indications while exploring portfolio diversification through its BEAMED surgical laser technology.

Host Defense Protein (HDP)-mimetic platform, creating synthetic small molecules that mimic the structure and multi-functional (antimicrobial, immunomodulatory, anti-inflammatory) properties of natural defensins.

In Oral Mucositis, Brilacidin competes against palliative standard of care, with an opportunity to be first-to-market for prevention. In antibiotics, it faces entrenched competitors but differentiates via a novel mechanism and single-dose potential. In IBD, it enters a crowded market but with a unique, localized, non-biologic mechanism of action.